Clinical applications of advanced lipoprotein testing in diabetes mellitus

Clinical Lipidology

Volumn 6, Issue 4, 2011, Pages 371-387

  Moin, Danyaal S ^a   Rohatgi, Anand ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

diabetes; lipoprotein; metabolic syndrome; particles

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ATORVASTATIN; BILE ACID SEQUESTRANT; COLESEVELAM; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FISH OIL; GLIBENCLAMIDE; GLICLAZIDE; GLUCAGON LIKE PEPTIDE 1; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; METFORMIN; NICOTINIC ACID; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; PRAVASTATIN; ROSIGLITAZONE; SIMVASTATIN; SITAGLIPTIN; SULFONYLUREA; TROGLITAZONE; UNINDEXED DRUG;

BLOOD GLUCOSE MONITORING; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; DIABETES MELLITUS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DYSLIPIDEMIA; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIPID ANALYSIS; LIPID COMPOSITION; LOW DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION; TREATMENT PLANNING;

EID: 80051992741     PISSN: 17460875     EISSN: 17584302     Source Type: Journal    
DOI: 10.2217/clp.11.37     Document Type: Review

References (84)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27(5), 1047-1053 (2004) (Pubitemid 38579764)
2. Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993. Diabetes Care 21(7), 1138-1145 (1998) (Pubitemid 28368522)
3. Merz CN, Buse JB, Tuncer D, Twillman GB. Physician attitudes and practices and patient awareness of the cardiovascular complications of diabetes. J. Am. Coll. Cardiol. 40(10), 1877-1881 (2002) (Pubitemid 35341969)
4. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 44(Suppl. 2), S14-S21 (2001) (Pubitemid 32844108)
5. Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 100(10), 1134-1146 (1999) (Pubitemid 29416243)
6. American Diabetes Association. Standards of medical care in diabetes - 2006. Diabetes Care 29(Suppl. 1), S4-S42 (2006)
7. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285(19), 2486-2497 (2001)
8. Fox CS, Coady S, Sorlie PD, et al. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation 115(12), 1544-1550 (2007) (Pubitemid 46648639)
9. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 114(6), 597-605 (2006) (Pubitemid 44199649)
10. Lossow WJ, Lindgren FT, Murchio JC, Stevens GR, Jensen LC. Particle size and protein content of six fractions of the Sf 20 plasma lipoproteins isolated by density gradient centrifugation. J. Lipid Res. 10(1), 68-76 (1969)
11. Krauss RM, Burke DJ. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J. Lipid Res. 23(1), 97-104 (1982) (Pubitemid 12112617)
12. Otvos JD, Jeyarajah EJ, Bennett DW, Krauss RM. Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. Clin. Chem. 38(9), 1632-1638 (1992)
13. Ip S, Lichtenstein AH, Chung M, Lau J, Balk EM. Systematic review: association of low-density lipoprotein subfractions with cardiovascular outcomes. Ann. Intern. Med. 150(7), 474-484 (2009)
14. Chung M, Lichtenstein AH, Ip S, Lau J, Balk EM. Comparability of methods for LDL subfraction determination: a systematic review. Atherosclerosis 205(2), 342-348 (2009)
15. Rosenson RS, Brewer HB Jr, Chapman MJ, et al. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin. Chem. 57(3), 392-410 (2011)
16. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106(25), 3143-3421 (2002)
17. Cui Y, Blumenthal RS, Flaws JA, et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch. Intern. Med. 161(11), 1413-1419 (2001) (Pubitemid 32681162)
18. Arsenault BJ, Rana JS, Stroes ES, et al. Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women. J. Am. Coll. Cardiol. 55(1), 35-41 (2009)
19. Brook RD, Kansal M, Bard RL, Eagle K, Rubenfire M. Usefulness of low-density lipoprotein particle size measurement in cardiovascular disease prevention. Clin. Cardiol. 28(11), 534-537 (2005) (Pubitemid 41608274)
20. Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation 112(22), 3375-3383 (2005) (Pubitemid 43739551)
21. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 82(2), 495-506 (1990) (Pubitemid 20257828)
22. Lamarche B, Tchernof A, Moorjani S, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 95(1), 69-75 (1997) (Pubitemid 27029945)
23. Griffin BA, Skinner ER, Maughan RJ. Plasma high density lipoprotein subfractions in subjects with different coronary risk indices as assessed by plasma lipoprotein concentrations. Atherosclerosis 70(1-2), 165-169 (1988) (Pubitemid 18091714)
24. Cheung MC, Brown BG, Wolf AC, Albers JJ. Altered particle size distribution of apolipoprotein A-I-containing lipoproteins in subjects with coronary artery disease. J. Lipid Res. 32(3), 383-394 (1991)
25. Kontush A, Chantepie S, Chapman MJ. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler. Thromb. Vasc. Biol. 23(10), 1881-1888 (2003) (Pubitemid 37254879)
26. Goldberg IJ. Clinical review 124: Diabetic dyslipidemia: causes and consequences. J. Clin. Endocrinol. Metab. 86(3), 965-971 (2001) (Pubitemid 32322966)
27. Siegel RD, Cupples A, Schaefer EJ, Wilson PW. Lipoproteins, apolipoproteins, and low-density lipoprotein size among diabetics in the Framingham offspring study. Metabolism 45(10), 1267-1272 (1996) (Pubitemid 26337674)
28. Feingold KR, Grunfeld C, Pang M, Doerrler W, Krauss RM. LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. Arterioscler. Thromb. 12(12), 1496-1502 (1992)
29. Tan CE, Chew LS, Chio LF, et al. Cardiovascular risk factors and LDL subfraction profile in Type 2 diabetes mellitus subjects with good glycaemic control. Diabetes Res. Clin. Pract. 51(2), 107-114 (2001) (Pubitemid 32140862)
30. Haffner SM, Mykkanen L, Stern MP, Paidi M, Howard BV. Greater effect of diabetes on LDL size in women than in men. Diabetes Care 17(10), 1164-1171 (1994) (Pubitemid 24307452)
31. Friedlander Y, Kidron M, Caslake M, Lamb T, Mcconnell M, Bar-On H. Low density lipoprotein particle size and risk factors of insulin resistance syndrome. Atherosclerosis 148(1), 141-149 (2000)
32. Selby JV, Austin MA, Newman B, et al. LDL subclass phenotypes and the insulin resistance syndrome in women. Circulation 88(2), 381-387 (1993) (Pubitemid 23228036)
33. Grundy SM. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am. J. Cardiol. 81(4A), 18B-25B (1998) (Pubitemid 28113941)
34. Drexel H, Aczel S, Marte T, Vonbank A, Saely CH. Factors predicting cardiovascular events in statin-treated diabetic and non-diabetic patients with coronary atherosclerosis. Atherosclerosis 208(2), 484-489 (2010)
35. Berneis K, Jeanneret C, Muser J, Felix B, Miserez AR. Low-density lipoprotein size and subclasses are markers of clinically apparent and non-apparent atherosclerosis in Type 2 diabetes. Metabolism 54(2), 227-234 (2005) (Pubitemid 40174852)
36. Syvanne M, Ahola M, Lahdenpera S, et al. High density lipoprotein subfractions in non-insulin-dependent diabetes mellitus and coronary artery disease. J. Lipid Res. 36(3), 573-582 (1995)
37. Williams PT, Krauss RM, Vranizan KM, Stefanick ML, Wood PD, Lindgren FT: Associations of lipoproteins and apolipoproteins with gradient gel electrophoresis estimates of high density lipoprotein subfractions in men and women. Arterioscler. Thromb. 12(3), 332-340 (1992)
38. Stefanovic A, Kotur-Stevuljevic J, Spasic S, et al. HDL 2 particles are associated with hyperglycaemia, lower PON1 activity and oxidative stress in Type 2 diabetes mellitus patients. Clin. Biochem. 43(15), 1230-1235 (2010)
39. Festa A, Williams K, Hanley AJ, et al. Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the Insulin Resistance Atherosclerosis Study. Circulation 111(25), 3465-3472 (2005) (Pubitemid 40923401)
40. Austin MA, Mykkanen L, Kuusisto J, et al. Prospective study of small LDLs as a risk factor for non-insulin dependent diabetes mellitus in elderly men and women. Circulation 92(7), 1770-1778 (1995)
41. Hodge AM, Jenkins AJ, English DR, O'dea K, Giles GG. NMR-determined lipoprotein subclass profile predicts Type 2 diabetes. Diabetes Res. Clin. Pract. 83(1), 132-139 (2009)
42. Lu J, Jiang W, Yang JH, et al. Electronegative LDL impairs vascular endothelial cell integrity in diabetes by disrupting fibroblast growth factor 2 (FGF2) autoregulation. Diabetes 57(1), 158-166 (2008)
43. Chen CH, Jiang T, Yang JH, et al. Low-density lipoprotein in hypercholesterolemic human plasma induces vascular endothelial cell apoptosis by inhibiting fibroblast growth factor 2 transcription. Circulation 107(16), 2102-2108 (2003) (Pubitemid 36532191)
44. Mcneill KL, Fontana L, Russell-Jones DL, Rajman I, Ritter JM, Chowienczyk PJ. Inhibitory effects of low-density lipoproteins from men with type II diabetes on endothelium-dependent relaxation. J. Am. Coll. Cardiol. 35(6), 1622-1627 (2000) (Pubitemid 30307509)
45. Skyrme-Jones RA, O'brien RC, Luo M, Meredith IT. Endothelial vasodilator function is related to low-density lipoprotein particle size and low-density lipoprotein vitamin E content in Type 1 diabetes. J. Am. Coll. Cardiol. 35(2), 292-299 (2000) (Pubitemid 30125516)
46. Kathiresan S, Otvos JD, Sullivan LM, et al. Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation 113(1), 20-29 (2006) (Pubitemid 43958484)
47. Gazi I, Tsimihodimos V, Filippatos T, Bairaktari E, Tselepis AD, Elisaf M. Concentration and relative distribution of low-density lipoprotein subfractions in patients with metabolic syndrome defined according to the National Cholesterol Education Program criteria. Metabolism 55(7), 885-891 (2006) (Pubitemid 43902890)
48. Rizzo M, Pernice V, Frasheri A, et al. Small, dense low-density lipoproteins (LDL) are predictors of cardio- and cerebro-vascular events in subjects with the metabolic syndrome. Clin Endocrinol. (Oxf.) 70(6), 870-875 (2009)
49. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among u.s. adults. Diabetes Care 27(10), 2444-2449 (2004) (Pubitemid 39281399)
50. Otvos JD, Mora S, Shalaurova I, Greenland P, Mackey RH, Goff DC Jr. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J. Clin. Lipidol. 5(2), 105-113 (2011)
51. Halle M, Berg A, Garwers U, et al. Influence of 4 weeks' intervention by exercise and diet on low-density lipoprotein subfractions in obese men with Type 2 diabetes. Metabolism 48(5), 641-644 (1999) (Pubitemid 29230527)
52. Wagner AM, Jorba O, Rigla M, et al. Effect of improving glycemic control on low-density lipoprotein particle size in Type 2 diabetes. Metabolism 52(12), 1576-1578 (2003) (Pubitemid 38049274)
53. Caixas A, Ordonez-Llanos J, De Leiva A, Payes A, Homs R, Perez A. Optimization of glycemic control by insulin therapy decreases the proportion of small dense LDL particles in diabetic patients. Diabetes 46(7), 1207-1213 (1997) (Pubitemid 27271083)
54. Rivellese AA, Patti L, Romano G, et al. Effect of insulin and sulfonylurea therapy, at the same level of blood glucose control, on low density lipoprotein subfractions in Type 2 diabetic patients. J. Clin. Endocrinol. Metab. 85(11), 4188-4192 (2000) (Pubitemid 32055371)
55. Ohira M, Miyashita Y, Ebisuno M, et al. Effect of metformin on serum lipoprotein lipase mass levels and LDL particle size in Type 2 diabetes mellitus patients. Diabetes Res. Clin. Pract. 78(1), 34-41 (2007) (Pubitemid 47354216)
56. Bavirti S, Ghanaat F, Tayek JA. Peroxisome proliferator-activated receptor-gamma agonist increases both low-density lipoprotein cholesterol particle size and small high-density lipoprotein cholesterol in patients with Type 2 diabetes independent of diabetic control. Endocr. Pract. 9(6), 487-493 (2003)
57. Lawrence JM, Reid J, Taylor GJ, Stirling C, Reckless JP. Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early Type 2 diabetes. Diabetes Care 27(1), 41-46 (2004) (Pubitemid 38196707)
58. Nakano K, Hasegawa G, Fukui M, et al. Effect of pioglitazone on various parameters of insulin resistance including lipoprotein subclass according to particle size by a gel-permeation high-performance liquid chromatography in newly diagnosed patients with Type 2 diabetes. Endocr. J. 57(5), 423-430 (2010)
59. Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with Type 2 diabetes and dyslipidemia. Diabetes Care 28(7), 1547-1554 (2005) (Pubitemid 40923063)
60. Deeg MA, Buse JB, Goldberg RB, et al. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with Type 2 diabetes and dyslipidemia. Diabetes Care 30(10), 2458-2464 (2007) (Pubitemid 47547772)
61. Berneis K, Rizzo M, Stettler C, et al. Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with Type 2 diabetes. Expert Opin. Pharmacother. 9(3), 343-349 (2008) (Pubitemid 351291781)
62. Horton ES, Silberman C, Davis KL, Berria R. Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with Type 2 diabetes receiving incretin therapies or insulin in a large cohort database. Diabetes Care 33(8), 1759-1765 (2010)
63. Hsieh J, Longuet C, Baker CL, et al. The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia 53(3), 552-561 (2010)
64. Soedamah-Muthu SS, Colhoun HM, Thomason MJ, et al. The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in Type 2 diabetic patients with ischaemic heart disease. Atherosclerosis 167(2), 243-255 (2003) (Pubitemid 36773524)
65. Charlton-Menys V, Betteridge DJ, Colhoun H, et al. Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in Type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS). Clin. Chem. 55(3), 473-480 (2009)
66. Kappelle PJ, Dallinga-Thie GM, Dullaart RP. Atorvastatin treatment lowers fasting remnant-like particle cholesterol and LDL subfraction cholesterol without affecting LDL size in Type 2 diabetes mellitus: relevance for non-HDL cholesterol and apolipoprotein B guideline targets. Biochim. Biophys. Acta 1801(1), 89-94 (2010)
67. Lee SJ, Sacks FM. Effect of pravastatin on intermediate-density and low-density lipoproteins containing apolipoprotein CIII in patients with diabetes mellitus. Am. J. Cardiol. 92(2), 121-124 (2003) (Pubitemid 36835957)
68. Rosenson R. Colesevelam HCl reduces LDL particle number and increases LDL size in hypercholesterolemia. Atherosclerosis 185(2), 327-330 (2006)
69. Rosenson RS, Abby SL, Jones MR. Colesevelam HCl effects on atherogenic lipoprotein subclasses in subjects with Type 2 diabetes. Atherosclerosis 204(2), 342-344 (2009)
70. Berneis K, Rizzo M, Berthold HK, Spinas GA, Krone W, Gouni-Berthold I. Ezetimibe alone or in combination with simvastatin increases small dense low-density lipoproteins in healthy men: a randomized trial. Eur. Heart J. 31(13), 1633-1639 (2010)
71. Ose L, Reyes R, Johnson-Levonas AO, Sapre A, Tribble DL, Musliner T. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques. Clin. Ther. 29(11), 2419-2432 (2007)
72. Nakou ES, Filippatos TD, Agouridis AP, Kostara C, Bairaktari ET, Elisaf MS. The effects of ezetimibe and/or orlistat on triglyceride-rich lipoprotein metabolism in obese hypercholesterolemic patients. Lipids 45(5), 445-450 (2010)
73. Vakkilainen J, Steiner G, Ansquer JC, et al. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 107(13), 1733-1737 (2003) (Pubitemid 36418352)
74. Mostad IL, Bjerve KS, Lydersen S, Grill V. Effects of marine n-3 fatty acid supplementation on lipoprotein subclasses measured by nuclear magnetic resonance in subjects with Type II diabetes. Eur. J. Clin. Nutr. 62(3), 419-429 (2008) (Pubitemid 351356583)
75. Patti L, Maffettone A, Iovine C, et al. Long-term effects of fish oil on lipoprotein subfractions and low density lipoprotein size in non-insulin-dependent diabetic patients with hypertriglyceridemia. Atherosclerosis 146(2), 361-367 (1999) (Pubitemid 29418068)
76. Baumstark MW, Frey I, Berg A, Keul J. Influence of n-3 fatty acids from fish oils on concentration of high- and low-density lipoprotein subfractions and their lipid and apolipoprotein composition. Clin. Biochem. 25(5), 338-340 (1992)
77. Mckenney JM, McCormick LS, Schaefer EJ, Black DM, Watkins ML. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. Am. J. Cardiol. 88(3), 270-274 (2001) (Pubitemid 32721954)
78. Kuvin JT, Dave DM, Sliney KA, et al. Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am. J. Cardiol. 98(6), 743-745 (2006) (Pubitemid 44301006)
79. Pan J, Lin M, Kesala RL, Van J, Charles MA. Niacin treatment of the atherogenic lipid profile and Lp(a) in diabetes. Diabetes Obes. Metab. 4(4), 255-261 (2002) (Pubitemid 34814866)
80. Lai E, De Lepeleire I, Crumley TM, et al. Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1. Clin. Pharmacol. Ther. 81(6), 849-857 (2007) (Pubitemid 46788299)
81. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361(9374), 2005-2016 (2003)
82. Chung BH, Segrest JP, Ray MJ, et al. Single vertical spin density gradient ultracentrifugation. Methods Enzymol. 128, 181-209 (1986) (Pubitemid 16100892)
83. Warnick GR, Mcnamara JR, Boggess CN, Clendenen F, Williams PT, Landolt CC. Polyacrylamide gradient gel electrophoresis of lipoprotein subclasses. Clin. Lab. Med. 26(4), 803-846 (2006) (Pubitemid 44716509)
84. Garvey WT, Kwon S, Zheng D, et al. Effects of insulin resistance and Type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 52(2), 453-462 (2003) (Pubitemid 36173203)